you seem to think everything [0]=92524&c[visible]=1']is a slur...

you seem to think everything is a slur dolce. But either way, your powers of comprehension appear to have let you down again:

I responded to this: "Why would the Data Monitoring Committee allow the trial to continue"

with this direct response.

"At the first interim they were to be provided with a yes/no answer to whether the surrogate efficacy endpoints had been met. The only way the DMC would have ended the trial at the first interim was for safety."

As to Silviu's compensation, that's a matter of public record, not a slur:




That's quite some salary for a pre revenue company don't you think?

The Journal of Clinical Oncology published some interesting thoughts on why trials progress beyond where they should:

“if the fortunes of the entire company depend on the fate of a single phase II compound, and the interests of those deciding whether or not to enter phase III are tied entirely to the ongoing viability of the company, it would hardly seem surprising that companies push forward with the development of drugs when to objective outside observers further development seems futile.”​

​

“Given a set of questionable phase II data, the stock price of a company would suffer far more if management concluded it would be improper to expend shareholder capital on a phase III program likely to fail than if management decided to forge ahead into phase III on the basis of some dubious, post hoc subgroup analyses”.​

​

“[As] those directing the drug development path have multiple, profound incentives to move programs into phase III….it is easy for [a] management team to run phase II programs unlikely to generate reliable data but likely to generate a false-positive signal [that could justify progression to phase III]. For the unscrupulous, these same types of phase II programs are an easy path to a “promising” phase III cancer drug that can mean a high stock price and enormous personal riches”.​

​

Source: Dr Tony Fiorino, JCO July 1, 2007 vol. 25 no. 19 e21-e23​